A Cambridge, Mass., biotech says it has signed a deal with Swiss drug giant  Roche (ROG) to develop new medicines to combat drug-resistant “superbugs,” three weeks after the World Health Organization said the world is running out of effective antibiotics.

Warp Drive Bio has been working for over a year to identify more than 100 new classes of potential antibiotics, using what it calls “genome mining platform” — including a vast database of genetic material that corresponds to more than 135,000 bacterial strains.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy